This systematic review aimed to assess the detection rates of clinically significant (CSC) and clinically insignificant cancer (CIC) by MRI-targeted biopsy compared to systematic biopsy in men with suspected prostate cancer.
INTRODUCTION AND OBJECTIVES: MRI-targeted biopsy (MRI-TB) is a diagnostic test strategy that serves as an alternative to systematic prostate biopsy.
This systematic review aimed to assess the detection rates of clinically significant (CSC) and clinically insignificant cancer (CIC) by MRI-targeted biopsy compared to systematic biopsy in men with suspected prostate cancer.
METHODS: A literature search was carried out using Embase, PubMed, Web of Science, Cochrane library and Clinicaltrials.gov databases using search terms including: "biopsy", "MRI" and "prostate" and variations of these. For inclusion, each paper needed to specify cancer detection rates from the biopsies taken only from MRI suspicious areas. Systematic biopsy included 10 to 12 core ultrasound guided transrectal (TRUS) or transperineal template mapping (TPM) biopsy. The methodological quality of included studies was assessed using a modified QUADAS-2 checklist. CSC was defined as Gleason score 3þ4 or greater and CIC as Gleason score 3þ3, unless otherwise specified by the study. A detection ratio (DR) was calculated as the proportion of men with the target condition in the MRI-TB arm divided by the proportion in the systematic biopsy arm. A DR > 1 indicated that MRI-TB detected the target condition more frequently than systematic biopsy. For each target condition, DRs were pooled using random effects meta-analysis. Differences between subgroups were formally assessed with univariate meta-regression. RESULTS: More than 7000 studies were screened. For CSC detection, 73 studies (5906 patients) were included. MRI-TB had a higher detection rate for CSC than systematic biopsy (DR, 1.12 [95% CI 1.07-1.18], p <0.001), though meta-regression showed that this depended on the type of systematic biopsy (p [ 0.053), with MRI-TB performing slightly better compared to TRUS biopsy than compared to TPM biopsy. MRI-TB had higher detection rates irrespective of prior biopsy status (p [ 0.91) Pre-biopsy multiparametric MRI (mpMRI) is increasingly used in prostate cancer diagnosis. The reported negative predictive value (NPV) of mpMRI is used by some clinicians to aid decision making about whether or not to proceed to biopsy. Our contemporary systematic review update of the NPV of mpMRI for clinically significant prostate cancer reflects the latest literature on optimal mpMRI techniques and scoring systems, and aims to provide the latest NPV of mpMRI in this setting.
METHODS: We conducted a systematic literature search and included studies from 2016-2018 which assessed the NPV of mpMRI for clinically significant prostate cancer, using biopsy or clinical followup as the reference standard. To ensure that studies included in this analysis reflect contemporary practice, we only included studies in which mpMRIs were interpreted according to the PIRADS or similar institutional Likert grading system. We define a negative mpMRI as either (1) PIRADS/Likert 1-2 or (2) PIRADS/Likert 1-3. Clinically significant prostate cancer (csPCa) was defined as either (1) Gleason grade group !2 or (2) Gleason grade group !3. We calculated NPV separately for each combination of negative mpMRI and csPCa. The protocol was registered a priori in PROSPERO [CRD42018111619] .
RESULTS: A total of 24 studies with 3,903 patients met our inclusion criteria and were included for analysis. 11 studies (45.8%) included only biopsy naïve patients, and a further 9 studies (37.5%) included a mixed population of both biopsy-naïve and previous negative biopsy patients. 13 studies (54.2%) performed mpMRI using a 3T scanner, and 5 (20.8%) used both 1.5T and 3T. The majority of studies (70.8%) interpreted their mpMRI according to PIRADS. Studies were assessed for bias as low to moderate.
Using definition (1) for a negative mpMRI (PIRADS/Likert 1-2) and clinically significant cancer (Gleason grade group !2), the pooled NPV was 91.7% . When defining csPCa using definition (2) (Gleason grade group !3), the NPV for csPCa was 96.7% .
Four studies allowed calculation of the pooled NPV using definition (2) for negative mpMRI (PIRADS/Likert 1-3) and definition (1) for clinically significant disease: 85.0% . Using definition (2) for both negative mpMRI and clinically significant disease, the pooled NPV from two studies was 95.1% [95] [96] [97] .0%].
CONCLUSIONS: These NPV figures should aid decision making regarding whether to proceed to biopsy in men with an elevated age-specific PSA and an mpMRI reported as PIRADS/Likert 1-2 or 1-3. Additional risk stratification tools can be used to minimise the risk of missing clinically significant disease.
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